AI Framework Discovers 7 New Lifespan-Extending Compounds Using Gene Expression Maps
Researchers built a transcriptomic model that predicted and validated 10 geroprotective compounds, 7 never before reported, extending lifespan in C. elegans.
Summary
Many longevity-drug screens assume that any gene activity change with age is bad, and that a good drug should reverse it. This study challenges that idea. Researchers sequenced aging roundworms and sorted thousands of genes into coexpression groups called modules. They found that some age-related changes are protective responses, partly driven by the longevity gene daf-16. Using modules linked to life span across 25 datasets, they predicted which compounds might extend life. Ten compounds, seven never reported before, extended worm life span when tested. Two top candidates shifted the predicted modules as expected. Several of the same modules were also preserved in aging mice and tracked with frailty, which suggests the approach may carry over to mammals.
Detailed Summary
Finding drugs that slow aging usually means looking for compounds that make an old gene expression profile look young. This study questions that logic. The researchers argue that part of the aging transcriptome is adaptive, meaning the body turns these changes on to cope with damage. If so, reversing every age-related change may not be beneficial, and some interventions may work partly by inducing aging-like protective responses. The authors also note that most known geroprotectors belong to a few well-studied classes, such as mTOR inhibitors, AMPK activators and HDAC inhibitors. Existing transcriptomic approaches have limits: the 'reversal' approach assumes all age-related changes are harmful, and the 'mimic' approach tends to rediscover drugs similar to known ones.
The team sequenced C. elegans at five ages (days 6, 8, 11, 14 and 18, six replicates each), plus 30 wild-type and 20 short-lived daf-16(mu86) mutant samples collected at day 6. They built a transcriptomic aging clock on principal components, and PC1 correlated strongly with age (Spearman rho 0.88). The clock detected accelerated aging in daf-16 mutants (+0.52, P = 2.6 x 10-6) and delayed aging in long-lived eat-2 mutants (-4.04, P = 7 x 10-5). Yet when applied to worms treated with life span-extending drugs, most treatments looked older, not younger. Only rapamycin lowered predicted age. A second published clock (BitAge) also failed to show younger transcriptomic ages in drug-treated worms.
To untangle this, the authors used weighted gene coexpression network analysis. It produced 38 main modules and 62 submodules. Of the 62, 39 were age-associated, 26 responded to daf-16, and 19 responded to both. Twelve of those 19 moved in opposite directions with aging and daf-16 loss, which suggests adaptive responses. Mitochondrial modules M11 and M2.4 fell between days 6 and 14 and then rose by day 18, while their correlation dropped from 0.93 to 0.79. The authors read this as loss of coordinated control late in life.
A meta-analysis of 25 RNA-seq datasets of genetic and drug interventions linked 15 modules to longevity (FDR 0.1 or lower), including 6 at FDR 0.05 or lower. Ten were negatively associated, meaning that lower expression went with longer life span. These included the mitochondrial modules M11 and M2.4 and the ribosomal module M27, which showed the strongest association. The daf-16-target modules M20 and M1.3 were positively associated (FDR = 7.4 x 10-5).
Using these longevity-associated modules as signatures, the team ran a small-scale compound screen. It validated 10 life span-extending compounds in C. elegans, 7 of them previously unreported. RNA-seq of two top candidates showed targeted modulation of the predicted modules. Several modules, including M27, M2.4 and M11, were preserved in most mouse tissues in the Tabula Muris Senis data (not liver). They were also preserved in soleus muscle RNA-seq from mice aged 6, 12, 20 and 28 months (Zsummary 12.3 to 25.5). According to the abstract, they also correlated with frailty.
The approach offers a way to prioritize compounds beyond well-known drug classes. Caveats are that the screen was small and done in worms, and that human translation is untested. Only a subset of worm genes have mammalian orthologs. Module direction can also depend on context, since M11 and M27 behaved differently under dietary restriction than under drug or genetic interventions.
Key Findings
- A PC1-based transcriptomic clock correlated strongly with age (Spearman rho = 0.88) and flagged accelerated aging in daf-16 mutants (+0.52, P = 2.6e-6) and delayed aging in eat-2 mutants (-4.04, P = 7e-5)
- Most life span-extending drugs made worms look transcriptomically older, and only rapamycin lowered predicted age, which undermines the 'reverse the aging signature' strategy
- Network analysis yielded 38 main modules and 62 submodules; 39 were age-associated, 26 responded to daf-16, and 12 of the 19 responding to both moved in opposite directions, consistent with adaptive responses
- A meta-analysis of 25 RNA-seq datasets linked 15 modules to longevity (FDR 0.1 or lower), led by the ribosomal module M27, and the daf-16-target modules M20 and M1.3 showed the strongest positive associations (FDR = 7.4e-5)
- Module-based prediction led to 10 validated life span-extending compounds in C. elegans, 7 of them previously unreported
- RNA-seq of two top compounds showed targeted modulation of the longevity-associated modules
- Worm modules M27, M2.4 and M11 were preserved in aging mouse soleus muscle (Zsummary 12.3 to 25.5) and in most Tabula Muris Senis tissues except liver, and several modules correlated with mouse frailty
Methodology
The team performed RNA-seq on C. elegans at five ages (days 6 to 18, six replicates each) plus 30 wild-type and 20 daf-16(mu86) samples at day 6. They trained an elastic net PCA-based clock and built coexpression modules with WGCNA. Module activity was scored with GSVA and tested against reported median life span in a meta-analysis of 25 public RNA-seq datasets (random-effects and mixed-effects models). Cross-species conservation was tested with module preservation statistics in Tabula Muris Senis and in newly sequenced mouse soleus muscle at 6, 12, 20 and 28 months. Predicted compounds were then tested in worm life span assays.
Study Limitations
The screen was small and conducted mainly in C. elegans, and fewer than 7,000 worm genes have human or mouse orthologs. The mouse data came from specific tissues, and the worm modules were not preserved in liver. Some module associations were context-dependent, for example M11 and M27 under dietary restriction versus drug or genetic interventions. The full text provided was truncated, so the mouse frailty analysis, compound identities and conflicts of interest are not fully detailed here.
Enjoyed this summary?
Get the latest longevity research delivered to your inbox every week.
Enter your email to subscribe:
